Immunogenicity and immunization costs of adjuvanted versus non-adjuvanted hepatitis B vaccine in chronic kidney disease patients.
Hepatitis B virus (HBV) vaccination is recommended for all susceptible chronic pre-hemodialysis and hemodialysis patients. This study assessed the immunogenicity of HBV vaccines (adjuvanted and non-adjuvanted) in chronic kidney disease patients vaccinated at the Hospital Clinic of Barcelona (Spain) between January 2007 and July 2012. In addition, the costs for the health system were evaluated accor-ding to the proportion of vaccine responders after receiving either vaccine. Patients receiving 3 doses of hepatitis B adjuvanted vaccine were 3 times more likely to seroconvert than patients immunized with non-adjuvanted vaccines, OR 3.56 (95% CI 1.84-6.85). This resulted in fewer patients requiring a second course of HBV vaccination and fewer outpatient visits, saving more than €9,500 per 100 patients. The higher immunogenicity of the adjuvanted HBV vaccine would counterbalance the lower costs associated with the non-adjuvanted vaccine.
a Department of Preventive Medicine and Epidemiology , Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.|b ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.
Alba
A
Vilajeliu
a Department of Preventive Medicine and Epidemiology , Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.|b ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.
Víctor-Guillermo
VG
Sequera
b ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.|c Centro de Investigação em Saúde de Manhiça (CISM) , Maputo , Mozambique.|d Amsterdam Institute for Global Health and Development (AIGHD) , Amsterdam , The Netherlands.
Alberto L
AL
García-Basteiro
b ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.|e Department of Infectious Disease Epidemiology , Health Economics Group, School of Public Health, Imperial College London , London , UK.
Elisa
E
Sicuri
a Department of Preventive Medicine and Epidemiology , Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.|b ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.
Marta
M
Aldea
a Department of Preventive Medicine and Epidemiology , Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.|b ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.
César
C
Velasco
a Department of Preventive Medicine and Epidemiology , Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.|b ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona , Barcelona , Spain.
José M
JM
Bayas
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000191:economics*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D017048:Health Care Costs; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology*; D006761:Hospitals; D006801:Humans; D008297:Male; D008875:Middle Aged; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D012189:Retrospective Studies; D013030:Spain; D055815:Young Adult
D000276:Adjuvants, Immunologic; D017325:Hepatitis B Vaccines
AS04 hepatitis B vaccine; adjuvanted; chronic kidney disease; costs; hepatitis B vaccine; immunogenicity